急诊玻璃体切割术治疗严重眼外伤的开放性对照研究

注册号:

Registration number:

ChiCTR-OPN-16008799 

最近更新日期:

Date of Last Refreshed on:

2016-07-07 21:29:33 

注册时间:

Date of Registration:

2016-07-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

急诊玻璃体切割术治疗严重眼外伤的开放性对照研究

Public title:

Open controlled study of emergency vitrectomy for severe ocular trauma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

急诊玻璃体切割术治疗严重眼外伤的开放性对照研究

Scientific title:

Open controlled study of emergency vitrectomy for severe ocular trauma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汪方 

研究负责人:

刘勇 

Applicant:

Wang Fang 

Study leader:

Liu Yong 

申请注册联系人电话:

Applicant telephone:

+86 18375722981

研究负责人电话:

Study leader's
telephone:

+86 13983732105

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

659919036@qq.com

研究负责人电子邮件:

Study leader's E-mail:

liuyy99@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市沙坪坝区西南医院眼科

研究负责人通讯地址:

重庆市沙坪坝区西南医院眼科

Applicant address:

Dept. Ophthalmology, Southwest Hospital, 29 Gaotanyan Street, Shapingba District, Chongqing, China

Study leader's address:

Dept. Ophthalmology, Southwest Hospital, 29 Gaotanyan Street, Shapingba District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

400038

研究负责人邮政编码:

Study leader's postcode:

400038

申请人所在单位:

第三军医大学西南医院

Applicant's institution:

Southwest Hospital of Third Military Medical Universit

研究负责人所在单位:

第三军医大学西南医院

Affiliation of the Leader:

Southwest Hospital of Third Military Medical Universit

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2016-57

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

第三军医大学西南医院医学伦理委员会

Name of the ethic committee:

Ethic Committee of Southwest Hospital, Third Military Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2016-05-27 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

第三军医大学第一附属医院

Primary sponsor:

Southwest Hospital, Third Military Medical University

研究实施负责(组长)单位地址:

重庆市沙坪坝区高滩岩西南医院

Primary sponsor's address:

29 Gaotanyan Street, Shapingba District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

沙坪坝区

Country:

China

Province:

Chongqing

City:

Shapingba District

单位(医院):

第三军医大学西南医院

具体地址:

重庆市沙坪坝区高滩岩西南医院

Institution
hospital:

Southwest Hospital of Third Military Medical University

Address:

29 Gaotanyan Street, Shapingba District, Chongqing, China

经费或物资来源:

Source(s) of funding:

no

研究疾病:

严重眼外伤  

Target disease:

severe ocular trauma

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

评价严重眼外伤介入急诊玻璃体手术的安全性及疗效  

Objectives of Study:

Evaluation of severe ocular trauma involved in the safety and efficacy of emergency vitrectomy

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.眼部的伴随情况/疾病
(1) 研究眼有阻碍研究治疗改善视力的伴随疾病
(2) 研究眼存在可能影响研究结果解释或可能导致损害视力或在6个月治疗期内需药物或手术干预治疗的其它疾病
(3) 研究眼存在全周睫状体脱离等影响手术后眼压控制的情况
2.全身情况或治疗
(1)凝血机能异常或目前正在使用抗凝药物(如阿司匹林)治疗者
(2)中风、冠心病、心绞痛史及肾功能不全需做透析或肾移植,以及其它不适合参与临床试验的全身慢性疾病
(3) 目前或近期可能需要全身使用已知对晶状体、视网膜或视神经有毒性的药物,包括氯喹/羟氯喹、吩噻嗪、乙胺丁醇、去铁敏和他莫昔芬等
3.依从性
(1)不能配合观察不良事件和疗效
(2)不能遵守研究或随访流程

Exclusion criteria:

1. With the eye / Disease:
(1) Study on the Eye hinder research to improve the treatment of diseases associated with vision;
(2) the study eye that could affect the interpretation of the results or may result in damage to eyesight or require medical or surgical intervention in the six-month period of treatment of other diseases;
(3) the presence of post-impact study eye intraocular pressure control of the entire circumference of the ciliary body detachment;
2. The general condition or treatment;
(1) or abnormal clotting function currently being used anticoagulant drugs (such as aspirin) treatment;
(2) stroke, coronary heart disease, history of angina and renal dysfunction require dialysis or kidney transplantation, and other unsuitable in a clinical trial of systemic chronic diseases;
(3) current or recent use may require general known to the lens, the retina or optic nerve toxic drugs, including chloroquine / hydroxychloroquine, phenothiazines, ethambutol, deferoxamine and tamoxifen, etc.;
3. Compliance
(1) can not be observed with the adverse events and efficacy;
(2) research or follow-up process can not comply.

研究实施时间:

Study execute time:

From 2016-07-01 00:00:00 To 2017-02-28 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-07-01 00:00:00 To 2017-01-31 00:00:00

干预措施:

Interventions:

组别:

玻璃体手术

样本量:

10

Group:

2

Sample size:

干预措施:

急诊48小时内一期清创缝合同时介入玻璃体手术

干预措施代码:

Intervention:

Within 48 hours of an emergency debridement while intervention vitrectomy

Intervention code:

组别:

对照

样本量:

10

Group:

Control

Sample size:

干预措施:

伤后早期行一期清创缝合术,在1-2周介入二期玻璃体手术

干预措施代码:

Intervention:

Intervention vitrectomy will be conducted after emergency debridement two weeks

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

第三军医大学西南医院 

单位级别:

3级甲等 

Institution
hospital:

Southwest Hospital, Third Military Medical University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

眼球保存率

指标类型:

主要指标

Outcome:

Eye preservation rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视网膜复位率

指标类型:

主要指标

Outcome:

Reattachment rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视力

指标类型:

主要指标

Outcome:

vision

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼压

指标类型:

次要指标

Outcome:

intraocular pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

未填写任何采集标本

组织:

Sample Name:

No sample added

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

方便选择

Randomization Procedure (please state who generates the random number sequence and by what method):

Convenience selection

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

西南医院眼科数据库,2016年08月30日

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Department of Ophthalmology, Southwest Hospital, 2016 30,, 08

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

西南医院眼科数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Department of Ophthalmology, Southwest Hospital, 2016 30,, 08

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2016-07-07 21:29:33